RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
A discrete choice experiment (DCE) to quantify the influence of trial features on the decision to participate in Cystic Fibrosis (CF) trials
Dobra, R., Davies, J., Elborn, J., Kee, F., Madge, S., & Boeri, M. (2022). A discrete choice experiment (DCE) to quantify the influence of trial features on the decision to participate in Cystic Fibrosis (CF) trials. Thorax - BMJ, 77, A114.3-A115. Article P62. https://doi.org/10.1136/thorax-2022-BTSabstracts.198
Background Patient-centred trial designs improve research quality and efficiency, ultimately allowing safe drugs to reach clinic more quickly. Our qualitative work suggests quantifying 6 key trial attributes could define priorities for patient-centred CF trials: type of medicine, trial design (placebo v open label), washout, stipend, location of visits, and post-trial drug access.